NEW YORK, Oct. 15, 2014 /PRNewswire/ -- Mariel Therapeutics, Inc., a clinical stage therapeutic company focusing on Bone Morphogenetic Protein-7 and its application in Osteoarthritis (OA) and Chronic Kidney Disease (CKD), today announced that the U.S. Patent and Trademark Office (USPTO) has issued two new patents related to BMP-7 in OA and CKD. The newly issued patents expand the already large intellectual property estate surrounding BMP-7, which include over 450 issues and pending patents, and extends important intellectual property in OA and CKD.
“These newly issued patents contain broad claims which provide important long-term exclusivity for BMP-7 and its use in OA and CKD,” said Joseph Hernandez, Chairman of Mariel Therapeutics. “Collectively, they further expand Mariel’s intellectual property estate surrounding BMP-7, enhancing its commercial potential.”
About Mariel Therapeutics, Inc.
Mariel Therapeutics, Inc. (Mariel) is a clinical stage biopharmaceutical company focused on the clinical application of Bone Morphogenetic Protein-7 (BMP-7) in osteoarthritis (OA), chronic kidney disease (CKD), and Alport’s Syndrome. Mariel acquired the rights to over 450 issued and pending patents as well as BMP-7-related clinical and research data, and the associated biologic materials from Stryker Corporation.
Human recombinant BMP-7 has previously been used in reconstructive bone applications in over 40,000 patients. Previous Phase I and Phase IIa trials have been completed in osteoarthritis. Mariel intends to advance clinical trial in osteoarthritis (OA) and for chronic kidney disease (CKD) and Alport’s disease, a genetic kidney fibrosis disease. For more info, please visit www.marieltherapeutics.com
CONTACT:
For more information on Mariel Therapeutics please contact:
Mariel Therapeutics, Inc.
646-475-2088; info@marieltherapeutics.com
www.MarielTherapeutics.com
SOURCE Mariel Therapeutics, Inc.
Help employers find you! Check out all the jobs and post your resume.
